Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer
THOUSAND OAKS, Calif., July 31, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AM... Biopharmaceuticals, Generics, Oncology, FDA Amgen, Allergan, ABP 980, Herceptin, (trastuzumab, Genentech, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Allergy | Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | HER2 | Herceptin | Marketing | Pharmaceuticals